The European commission is to push for a quota for women on company boards to address the slow progress to gender equality in the senior ranks of publicly listed businesses. Previous attempts by the EU’s executive to set a 40% goal for women in the top ranks of listed companies have been blocked by Germany, the Netherlands and Sweden overs fears that Brussels was overreaching into domestic affairs. Hungary and Poland have opposed the move on ideological grounds.
Egon Zehnder Istanbul recently hosted a presentation by Cozi Namer, Healthcare Industry Development Lead at Google, based in New York. As the subject of digital revolution continues to gain momentum in the performance-focused corporate world, healthcare industry is also in a state of constant transformation.
Disruption in healthcare will continue to be profound, widespread and unpredictable, regardless of what ultimately happens with the Affordable Care Act, or the recently introduced American Health Care Act of 2017.
Fundamental changes in the marketplace for medicines, as well as the rapid and continuing evolution of technology are bringing new challenges and opportunities for life sciences companies and their contribution to healthcare systems.
Healthcare has been in a state of steady, sometimes grudging, transformation for years. What’s different today is the dramatically accelerated pace of change that has been brought on by a combination of regulatory pressures, high costs, consumer empowerment, and revolutionary technological and medical innovation.
The generics industry has entered a phase of radical transformation. Rapid globalization, continuing consolidation, and increasing business complexity have turned formerly regional players into global operations.